Presentation exists across a continuum of severity determined by age and degree of AVP defect.
Older children present with sudden onset polyuria, nocturia, enuresis, and intense polydipsia.
Craving for ice-cold water classically highly suggestive.
Infants manifest nonspecific signs: irritability, failure to thrive, recurrent unexplained fever, and hypernatremic dehydration.
Excessive water ingestion limits caloric intake, causing severe nutritional failure to thrive.
Chronic massive urine volumes provoke nonobstructive hydronephrosis, hydroureter, and megabladder.
Mental retardation and intracerebral calcifications (frontal lobes/basal ganglia) occur in X-linked NDI following repeated dehydration episodes.
Concurrent cortisol deficiency (as seen in combined pituitary hormone deficiency) restricts free water clearance, masking polyuria until glucocorticoid therapy is initiated.
Post-neurosurgical DI classically follows a “triphasic response”.
Phase 1: Transient DI (12-48 hours) caused by local edema suppressing AVP.
Phase 2: Syndrome of inappropriate antidiuresis (SIAD) lasting up to 10 days, driven by unregulated AVP release from necrotic neurons.
Phase 3: Permanent DI ensuing if >90% of vasopressin neurons destroyed.
Diagnostic Evaluation
graph TD
Water Deprivation Test Phase
WaterDeprivation --> WDGoal[Goal: Elevate Plasma Osmolality >300 mOsm/kg or Na >146 mEq/L]
WDGoal --> WDExtreme{"Urine Osmolality appropriately >750 mOsm/kg"}
WDExtreme -- Yes --> NoDI
WDGoal --> WDPersist{"Persistent Urine Osmolality <300 mOsm/kg<br>despite hyperosmolality"}
WDPersist -- Yes --> DIConfirmed
Vasopressin Path
VasoTest --> VasoCentral{"Urine Osmolality rises >50% above baseline"}
VasoCentral -- Yes --> CentralDI([Central DI Diagnosis])
VasoTest --> VasoNDI{"Minimal or negligible increase"}
VasoNDI -- Yes --> NDI([Nephrogenic DI Diagnosis])
Neuroimaging Phase
CentralDI --> MRI[Neuroimaging: Gadolinium-Enhanced Brain MRI]
MRI --> MRINormal[Evaluate for absent 'bright spot', stalk thickening, or masses]
%% Styling
classDef testNode fill:#e1f5fe,stroke:#01579b,stroke-width:2px;
classDef resultNode fill:#e8f5e9,stroke:#2e7d32,stroke-width:2px,color:#000;
classDef condition fill:#fff3e0,stroke:#e65100,stroke-width:2px;
class InitScreen,Measure,WaterDeprivation,WDGoal,VasoTest,Copeptin,PostStim,MRI testNode;
class Exclude1,Confirm1,Equivocal,WDExtreme,WDPersist,Differentiation,VasoCentral,VasoNDI,CopNDI,CopCentral,CopPP condition;
class NoDI,DIConfirmed,CentralDI,NDI,PrimaryPoly resultNode;
Initial Biochemical Screening
Confirm pathologic polyuria (>2 L/m2/day or 5 mL/kg/hr).
Measure concurrent serum osmolality, serum sodium, urine osmolality, and urine specific gravity.
Definitive DI established if serum osmolality >300 mOsm/kg (or Na >146 mEq/L) simultaneously occurs with urine osmolality <300 mOsm/kg (specific gravity <1.005).
Serum osmolality <270 mOsm/kg or urine osmolality >600 mOsm/kg excludes DI diagnosis.
Water Deprivation Test
Indicated solely for patients with polyuria exhibiting low urine osmolality but normal baseline plasma osmolality.
Conducted strictly inpatient due to profound dehydration risk.
Goal: Elevate plasma osmolality >300 mOsm/kg (or Na >146 mEq/L) to provide maximal physiological stimulus for AVP release and renal concentration.
Monitor body weight, vital signs, urine output, and serial osmolality.
Terminate test immediately if weight loss exceeds 5%, serum Na exceeds 146 mEq/L, or urine osmolality appropriately surpasses 750 mOsm/kg (excluding DI).
Differentiates central DI from NDI following confirmation of DI.
Administer aqueous vasopressin injection (0.1 unit/kg) or subcutaneous desmopressin.
Urine osmolality rising >50% above baseline dictates central DI diagnosis.
Minimal or negligible increase diagnostic for NDI.
Copeptin Measurement
Copeptin constitutes the stable carboxy-terminus of the AVP precursor.
Validated superior biomarker compared to direct AVP measurement.
Baseline copeptin >20 pmol/L unequivocally confirms NDI without requiring fluid deprivation.
Following osmotic stimulus (hypertonic 3% saline), copeptin <4.9 pmol/L confirms central DI; >4.9 pmol/L indicates primary polydipsia.
Neuroimaging
Gadolinium-enhanced brain MRI mandatory for confirmed central DI.
Normal posterior pituitary demonstrates characteristic hyperintense “bright spot” on T1-weighted images.
“Bright spot” characteristically absent or attenuated in central DI.
Thickened pituitary stalk highly suggestive of Langerhans cell histiocytosis or lymphocytic infundibuloneurohypophysitis.
Essential to rule out occult germinomas, craniopharyngiomas, or midline malformations (septo-optic dysplasia).
Differential Diagnosis
Condition
Distinguishing Features
Primary Polydipsia
Compulsive water drinking. Characterized by baseline hyponatremia or low-normal serum osmolality. Normal posterior pituitary bright spot on MRI. Copeptin >4.9 pmol/L following hypertonic stimulus.
Osmotic Diuresis
Elevated urine output driven by solute load. Occurs in Diabetes Mellitus (glycosuria), mannitol administration, or post-obstructive diuresis.
Tubulopathy / Salt Loss
Polyuria with associated electrolyte wasting. Includes Bartter syndrome, Gitelman syndrome, and renal tubular acidosis.
Management
Central Diabetes Insipidus
Pharmacotherapy: Desmopressin (DDAVP), a synthetic AVP analog with potent V2-specific antidiuretic activity and prolonged half-life, remains treatment of choice.
Formulations include oral tablets, sublingual melts, or intranasal preparations.
Oral dosing typically 25 to 300 mcg every 8 to 12 hours.
Intranasal dosing (10 mcg/0.1 mL spray or rhinal tube) offers rapid onset.
Safety Protocol: Strict mandate to allow 1-hour urinary “breakthrough” daily before next dose administration. Prevents continuous antidiuresis leading to fatal water intoxication/hyponatremia.
Infant Management: Desmopressin avoided due to high obligate fluid intake causing hyponatremia. Managed primarily with high-volume fluid therapy utilizing low-renal-solute formulas (e.g., human milk). Thiazide diuretics employed to induce mild hypovolemia, enhancing proximal water reabsorption.
Acute Post-Neurosurgical DI: Managed with continuous intravenous aqueous vasopressin infusion (1.5 mU/kg/hr) due to rapid onset and short half-life (5-10 mins). Allows rapid titration and prevents masking of impending SIAD phase.
Nephrogenic Diabetes Insipidus
Treatment of underlying cause mandatory (correct hypokalemia/hypercalcemia, withdraw offending drugs like lithium).